OptimizeRx Corp. (OPRX)
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-11-05
$8.67-11.71%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-11-05
QuarterlyIQ Insights · OPRX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Despite some variability in second-half timing and mix, our first-half performance and commercial momentum give us confidence to reiterate full-year 2026 guidance of $95 million to $100 million in re…
Stated in 2 of 2 supplied quarters. Management reported: “Despite some variability in second-half timing and mix, our first-half performance and commercial momentum give us confidence to reiterate full-year 2026 guidance of $95 million to $100 million in revenue and $21 million to $25 million in adjusted EBITDA.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 42% for the rest of the cohort, n=10089).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Despite some variability in second-half timing and mix, our first-half performance and commercial momentum give us confidence to reiterate full-year 2026 guidance of $95 million to $100 million in re…”
“Rolling Twelve Months Ended March 31, Key Performance Indicators (KPIs)** 2026 2025 (in thousands, except percentages) Average revenue per top 20 pharmaceutical manufacturers $ 2,791 $ 2,963 Percent…”
Despite some variability in second-half timing and mix, our first-half performance and commercial momentum give us confidence to reiterate full-year 2026 guidance of $95 million to $100 million in re…
Stated in 2 of 2 supplied quarters. Management reported: “(See * Non-GAAP Measures below) • Adjusted EBITDA of $4.9 million in Q2 2026 compared to $5.8 million in Q2 2025.” “(see * Non-GAAP Measures below) • Adjusted EBITDA for the first quarter of 2026 increased to $3.3 million compared to $1.5 million in the same year ago period.”
“Despite some variability in second-half timing and mix, our first-half performance and commercial momentum give us confidence to reiterate full-year 2026 guidance of $95 million to $100 million in re…”
“Rolling Twelve Months Ended March 31, Key Performance Indicators (KPIs)** 2026 2025 (in thousands, except percentages) Average revenue per top 20 pharmaceutical manufacturers $ 2,791 $ 2,963 Percent…”
“Finally, we continued to strengthen our balance sheet by paying down $5.3 million of term loan principal during the quarter, $5.0 million ahead of schedule, and an additional $3.0 million subsequent…
Stated in 2 of 2 supplied quarters. Management reported: ““Finally, we continued to strengthen our balance sheet by paying down $5.3 million of term loan principal during the quarter, $5.0 million ahead of schedule, and an additional $3.0 million subsequent to quarter-end.” “• Subsequent to the end of the quarter, the Company refinanced its debt through Fifth Third Bank which lowers the interest rate by 625 basis points, an annual interest expense savings of approximately $1.5 million, through a $25 million term loan and an undrawn $10 million revolver.”
““Finally, we continued to strengthen our balance sheet by paying down $5.3 million of term loan principal during the quarter—$5.0 million ahead of schedule—and an additional $3.0 million subsequent t…”
“• Subsequent to the end of the quarter, the Company refinanced its debt through Fifth Third Bank which lowers the interest rate by 625 basis points, an annual interest expense savings of approximatel…”
We also expanded the long-term opportunity for OptimizeRx through three platform advancements: DeepIntent became the first healthcare demand-side platform (DSP) to integrate our authenticated electro…
Stated in 2 of 2 supplied quarters. Management reported: “We also expanded the long-term opportunity for OptimizeRx through three platform advancements: DeepIntent became the first healthcare demand-side platform (DSP) to integrate our authenticated electronic health record (EHR) network, we launched our patent-pending Natural Language Audience Builder, and we introduced CopayCue, our next-generation copay activation solution.” “As recently announced, we are also expanding our platform capabilities by opening our proprietary electronic health record network to demand-side platforms (DSPs), enabling media buyers to activate scalable, point of care campaigns within their clinical programmatic workflow.”
“We also expanded the long-term opportunity for OptimizeRx through three platform advancements: DeepIntent became the first healthcare demand-side platform (DSP) to integrate our authenticated electro…”
“As recently announced, we are also expanding our platform capabilities by opening our proprietary electronic health record network to demand-side platforms (DSPs), enabling media buyers to activate s…”
Appoint experienced independent directors to enhance strategic oversight and support company transformation.
Over the trailing year it converted 0.05x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
14 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 46% of the time over the next year (vs 44% for the rest of the cohort, n=13229).
Not investment advice. As of 2026-11-05.